SANOFI-AVENTIS Form 6-K March 01, 2006

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2006

Commission File Number: 001-31368

#### **SANOFI-AVENTIS**

(Translation of registrant

s name into English)

174, avenue de France, 75013 Paris, FRANCE (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F x o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If [Yes] marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

On February 28, 2006, sanofi-aventis issued the press releases attached hereto as Exhibit 99.1 and 99.2, which are incorporated herein by reference.

#### **Exhibit List**

Exhibit No.	<u>Description</u>
Exhibit 99.1	Press Release, dated February 28, 2006, announcing the availability in the United States of Apidra, a new
	rapid-acting insulin analog.
Exhibit 99.2	Press Release, dated February 28, 2006, announcing the rescheduling of the trial date in the United States
	Playix litigation

CI	GN	A -	TT I	D	CC

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 1, 2006 SANOFI-AVENTIS

By: /s/ Arthur Muratyan

Name: Arthur Muratyan
Title: Vice President
Corporate Law

3

#### **Exhibit Index**

Exhibit No.	<u>Description</u>
Exhibit 99.1	Press Release, dated February 28, 2006, announcing the availability in the United States of Apidra, a new
	rapid-acting insulin analog.
Exhibit 99.2	Press Release, dated February 28, 2006, announcing the rescheduling of the trial date in the United States
	Plavix litigation.